Anticancer agent-362
Anticancer agent-362 is a chimeric pyrrolidinedione-pyrrolidine-phthalazine-triazole (PPPT) heterocyclic derivative with antitumor activity. Anticancer agent-362 exhibits antiproliferative activity against breast adenocarcinoma and osteosarcoma cancer cell lines, with low toxicity to normal fibroblasts. Anticancer agent-362 is predicted to be a multi-target ligand that binds to the active sites of VEGFR-2, PARP-1, and others. Anticancer agent-362 can be used in research related to breast adenocarcinoma and osteosarcoma.
For research use only. We do not sell to patients.
- Formula: C28H22N6O4S
- Molecular Weight:538.58
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HOS | IC50 |
335.74 μM
|
Cytotoxicity against human osteosarcoma HOS cells assessed as reduction in cell viability using a seven-point concentration-response MTT assay.
Cytotoxicity against human osteosarcoma HOS cells assessed as reduction in cell viability using a seven-point concentration-response MTT assay.
|
j.bioorg.2026.110413 |
| MCF7 | IC50 |
222.81 μM
|
Cytotoxicity against human breast adenocarcinoma MCF7 cells assessed as reduction in cell viability using a seven-point concentration-response MTT assay.
Cytotoxicity against human breast adenocarcinoma MCF7 cells assessed as reduction in cell viability using a seven-point concentration-response MTT assay.
|
j.bioorg.2026.110413 |
| MG-63 | IC50 |
271.12 μM
|
Cytotoxicity against human osteosarcoma MG-63 cells assessed as reduction in cell viability using a seven-point concentration-response MTT assay.
Cytotoxicity against human osteosarcoma MG-63 cells assessed as reduction in cell viability using a seven-point concentration-response MTT assay.
|
j.bioorg.2026.110413 |
In Vitro
Anticancer agent-362 (compound 6J) (10-50 µM; 24 h) exhibits low toxicity toward normal HDF fibroblasts and shows excellent to moderate anticancer activity against MCF7, HOS, and MG-63 cancer cell lines[1].
Anticancer agent-362 has an IC50 = 431.29 μM against normal human dermal fibroblasts HDF, an IC50 = 335.74 μM against osteosarcoma HOS cells, an IC50 = 222.81 μM against breast cancer MCF7 cells, and an IC50 = 271.12 μM against osteosarcoma MG‑63 cells[1].
Anticancer agent-362 is predicted to act as a multi-target ligand that binds to the active pockets of VEGFR-2 and PARP-1[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:MCF7, HOS, and MG-63 cancer cell lines
-
Concentration:10, 50 µM
-
Incubation Time:24 h
-
Result:Demonstrated low toxicity against normal HDF fibroblasts and exhibits very good to moderate anticancer activity against MCF7, HOS, and MG-63 cancer cell lines.
Chemical Information
-
Molecular Weight 538.58
-
Formula C28H22N6O4S
-
SMILES
O=C1N(C2=CC=CC=C2)C([C@@]3([H])[C@]1([H])[C@H](C4=CN(S(=O)(C5=CC=C(C)C=C5)=O)N=N4)N6[C@@]3([H])C7=C(C=CC=C7)C=N6)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Anticancer agent-362 Related Classifications
HY-189264 Related Classifications
Powered by Bioz